Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-03-23
2008-08-05
Helms, Larry (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07407745
ABSTRACT:
By analyzing the mechanism for inducing a histone deacetylase inhibitor (Trichostatin A)-mediated expression of cyclin-CDK inhibitory factor having a proliferation suppressing effect (tumor-suppressing effect), it was revealed that the binding of Sp3 to the Sp1 binding sequence within a promoter is important in the expression of the above factor. Thus, a novel antitumor agent can be developed by screening a pharmaceutical agent capable of elevating Sp3 activity.
REFERENCES:
patent: 60-149520 (1985-08-01), None
patent: WO 92/05286 (1992-04-01), None
Sowa et al. (Cancer Research 1999. 59:4266-4270).
Majello et al (J Biological Chemistry, 1997, 272:4021-4026, IDS).
Kolell et al (Mol Biol Evl, 2002, 19:216-222).
Bowie et al (Science, 1990, 257:1306-1310).
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
Scott et al (Nature Genetics, 1999, 21:440-443).
Black et al (J of Cellular Physiology, 2001, 188:143-160).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Dictionary-MSN Encarta, “potential”, p. 1-3.
Allen et al (TIBS, 1995, 20:511-516).
Fields and Sternglanz (TIG, 1994, 10:287-292).
Zips et al (2005, In Vivo, 19:1-7).
Monneret, “Histone deacetylase inhibitors,” Eur. J. Med. Chem. 40:1-13 (2005).
Kim et al., “Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents,” J. Biochem. Mol. Biol. 36(1):110-119 (2003).
Hasegawa et al., “Cloning of a GADD34-like Gene That Interacts with the Zinc-Finger Transcription Factor Which Binds to the p21WAFPromoter”,Biochemical and Biophysical Research Communications. vol. 256(1). pp. 249-254 (1999).
Mo et al., “Down-Regulation of Topoisomerase Ila in CEM Cells Selected for Merbarone Resistance Is Associated with Reduced Expression of Sp31”,Cancer Research. vol. 57(22). pp. 5004-5008 (1997).
Dennig et al., “An inhibitor domain in Sp3 regulates its glutamine-rich activation domains”,The EMBO Journal, vol. 15(20). pp. 5659-5667 (1996).
Majello et al., “Sp3 Is a Bifunctional Transcription Regulator with Modular Independent Activation and Repression Domains”,The Journal of Biological Chemistry, vol. 272(7). pp. 4021-4026 (1997).
Lania et al., “Transcriptional Regulation by the Sp Family Proteins”,Int. J. Biochem. Cell. Biol., vol. 29(12), pp. 1313-1323 (1997).
Majello et al., “Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1”,Nucleic Acids Research. vol. 22(23), pp. 4914-4921 (1994).
Udvadia et al., “Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: Superactivation by Rb requires amino acids necessary for growth suppression”,Proc. Natl. Aca. Sci. USA. vol. 92(9), pp. 3953-3957 (1995).
Datto et al., “Functional Analysis of the Transforming Growth Factor β Responsive Elements in the WAF1/Cip1/p21 Promoter”, J. Biol. Chem., 270:28623-28628, 1995.
Nakajima et al., “FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor”, Exp. Cell Res., 241:126-133, 1998.
Nakano et al., “Butyrate Activates theWAFI/CipIGene Promoter through SP1 Sites in a p53-negative Human Colon Cancer Cell Line”, J. Biol. Chem., 272:22199-22206, 1997.
Sowa et al., “Sp3, but not Sp1, Mediates the Transcriptionsl Activation of the p21/WAF1/Cip1 Gene Promoter by Histone Deacetylase Inhibitor”, Cancer Res., 59:426604270, 1999.
Sowa et al., “Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites”, Biochem. Biophys. Res. Commun., 241:142-150, 1997.
Warrell, Jr., et al., “Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase”, J. Nat'l. Cancer Inst., 90:1621-1625, 1998.
Xiao et al., “Both Sp1 and Sp3 Are Responsible for p21waflPromoter Activity Induced by Histone Deacetylase Inhibitor in NIH3T3 Cells”, J. Cellular Biochem., 73:291-302, 1999.
Yoshida et al., “Potent and Specific Inhibition of Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A”, J. Biol. Chem., 265:17174-17179, 1990.
Orita Tetsuro
Sowa Yoshihiro
Chugai Seiyaku Kabushiki Kaisha
Fish & Richardson P.C.
Goddard Laura B
Helms Larry
LandOfFree
Method for screening anticancer agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening anticancer agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening anticancer agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4012521